Nurix Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Nurix Therapeutics, Inc. (NRIX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are NRIX insiders buying or selling?
In the last 12 months, Nurix Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 35 sales ($5.2M) — net selling of $5.2M. Since February 2021, Trabud has recorded 149 Form 4 filings for NRIX: 0 buys ($0) and 149 sells ($14.6M).
Source: SEC EDGAR Form 4
What stands out
- No Nurix Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 35 reported open-market sales totaled $5.2M.
Key Statistics (February 2021 – Oct 15, 2026)
Total Form 4 filings
149
SEC EDGAR
Insider filers
6
Insider buys (0)
$0
Insider sells (149)
$14.6M
Insider sentiment
Net sellingNet insider flow of $14.6M in net selling since February 2021, and $5.2M in net selling over the last 12 months.
Recent NRIX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 1.5K | $25.00 | $36.3K | SEC ↗ |
| Oct 14, 2026 | Julia P Gregory | Director | Sale | 22.6K | $23.40 | $528.5K | SEC ↗ |
| Oct 2, 2026 | Christine Ring | Chief Legal Officer | Sale | 5.8K | $23.19 | $134.1K | SEC ↗ |
| Sep 2, 2026 | Christine Ring | Chief Legal Officer | Sale | 5.8K | $25.76 | $149.1K | SEC ↗ |
| Sep 1, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 1.5K | $25.47 | $37.0K | SEC ↗ |
| Aug 5, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 4.4K | $25.00 | $108.9K | SEC ↗ |
| Aug 5, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 4.1K | $24.36 | $100.1K | SEC ↗ |
| Aug 5, 2026 | Houte Hans Van | Chief Financial Officer | Sale | 4.8K | $24.36 | $116.0K | SEC ↗ |
| Aug 3, 2026 | Christine Ring | Chief Legal Officer | Sale | 16.6K | $23.05 | $382.4K | SEC ↗ |
| Jul 30, 2026 | Houte Hans Van | Chief Financial Officer | Sale | 2.8K | $23.38 | $66.5K | SEC ↗ |
| Jul 30, 2026 | Christine Ring | Chief Legal Officer | Sale | 3.8K | $23.38 | $90.0K | SEC ↗ |
| Jul 30, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 3.8K | $23.38 | $90.0K | SEC ↗ |
| Jul 2, 2026 | Christine Ring | Chief Legal Officer | Sale | 11.0K | $23.56 | $259.4K | SEC ↗ |
| Jun 25, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 5.4K | $20.00 | $107.9K | SEC ↗ |
| Jun 25, 2026 | Christine Ring | Chief Legal Officer | Sale | 28.9K | $20.06 | $580.5K | SEC ↗ |
| Jun 2, 2026 | Christine Ring | Chief Legal Officer | Sale | 8.1K | $16.60 | $135.3K | SEC ↗ |
| May 5, 2026 | Houte Hans Van | Chief Financial Officer | Sale | 14.1K | $16.60 | $233.3K | SEC ↗ |
| May 4, 2026 | Christine Ring | Chief Legal Officer | Sale | 8.1K | $16.96 | $138.2K | SEC ↗ |
| May 1, 2026 | Christine Ring | Chief Legal Officer | Sale | 5.4K | $16.76 | $90.4K | SEC ↗ |
| Apr 30, 2026 | Houte Hans Van | Chief Financial Officer | Sale | 2.4K | $16.65 | $39.7K | SEC ↗ |
| Apr 30, 2026 | Christine Ring | Chief Legal Officer | Sale | 3.2K | $16.65 | $53.5K | SEC ↗ |
| Apr 30, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 3.2K | $16.65 | $53.5K | SEC ↗ |
| Apr 2, 2026 | Christine Ring | Chief Legal Officer | Sale | 8.1K | $15.24 | $124.1K | SEC ↗ |
| Mar 3, 2026 | Christine Ring | Chief Legal Officer | Sale | 8.1K | $15.44 | $125.8K | SEC ↗ |
| Feb 10, 2026 | Christine Ring | Chief Legal Officer | Sale | 14.3K | $16.66 | $237.6K | SEC ↗ |
Showing the 25 most recent of 149 Form 4 filings for Nurix Therapeutics, Inc..
Most active NRIX insiders
- Christine Ring62 filings
- Gwenn Hansen39 filings
- Houte Hans Van35 filings
- Pierre Beaurang7 filings
- Stefani Wolff5 filings
Ask anything about NRIX insider activity
Use Trabud's AI agent to query Nurix Therapeutics, Inc.'s Form 4 history in plain English — "Show me NRIX CEO purchases this year" or compare it against any other ticker.
Open the AI agentNRIX insider trading FAQ
Are Nurix Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Nurix Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 35 sales ($5.2M) — net selling of $5.2M. Since February 2021, Trabud has recorded 149 Form 4 filings for NRIX: 0 buys ($0) and 149 sells ($14.6M). Over the full record that is net selling of $14.6M.
How many insiders trade NRIX stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Nurix Therapeutics, Inc.. The most recent filing was accepted on Oct 15, 2026.
Where does Trabud get NRIX insider trading data?
All NRIX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.